A study published recently in the Journal of the American Medical Association has found that administering zoledronic acid every 12 weeks instead of the current standard of every four weeks over two years, does not increase the risk of skeletal-related events (SREs) in patients with bone complications due to breast cancer, prostate cancer or myeloma.…
Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. Chakraborty R et al. Blood Cancer J. 2016 Dec 16;6(12):e512. doi: 10.1038/bcj.2016.117. A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival. Botta C et al. Blood Cancer J. 2016 Dec 16;6(12):e511. doi: 10.1038/bcj.2016.118. 68Ga-PSMA PET/CT Imaging in Multiple Myeloma. Sasikumar A et…
Results from the national Myeloma XI trial have shown a higher incidence of second primary malignancies (SPM) in patients receiving Revlimid (lenalidomide) maintenance treatment compared to those who did not, in line with other previous reported trials. Published in the Blood Cancer Journal analysis of the data showed that, although the overall incidence of SPM was…
Celgene, the Dana-Farber Cancer Institute and the University of Arkansas for Medical Sciences (UAMS) have announced that they have partnered to create the Myeloma Genome Project to compile high quality genetic and clinical data to improve diagnosis, prognosis and treatment for myeloma patients. The aim is to develop a strategy for classifying myeloma into subgroups…
Improved MDCT monitoring of pelvic myeloma bone disease through the use of a novel longitudinal bone subtraction post-processing algorithm. Horger M et al. Eur Radiol. 2016 Nov 23. [Epub ahead of print]. Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma. Sawyer JR et al. Leukemia. 2016 Nov 4. doi: 10.1038/leu.2016.253. [Epub ahead of print]. Predictors of inferior clinical outcome in patients with…
A study, funded by Myeloma UK, has discovered a mechanism that may explain how a genetic variant increases the risk of developing myeloma. Published in the latest issue of Nature Communications, researchers at The Institute of Cancer Research, London investigated the functional effects of the most highly associated variant they had identified from a previously conducted…
The Myeloma UK Clinical Trial Network (CTN) has achieved another significant milestone with data from the MUK six trial published in the latest issue of Lancet Haematology. MUK six, a Phase I/II multicentre open label trial aimed to determine the safety and both the optimum and maximum dose of panobinostat when used in combination with once-weekly Velcade,…
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. Oliva S et al. Oncotarget. 2016 Oct 13. doi: 10.18632/oncotarget.12641. [Epub ahead of print]. The role of 68Ga-DOTA-TATE PET/CT scanning in the evaluation of patients with multiple myeloma: preliminary results. Sonmezoglu K et al. Nucl Med Commun. 2016 Oct 21. [Epub ahead of print]. Whole body magnetic resonance imaging in…
A Myeloma UK funded study, published recently in the European Journal of Haematology, has found that a large number of symptoms occur frequently in myeloma patients, highlighting the importance of routine assessments throughout the disease trajectory in order to achieve optimal quality of life for patients. Led by Christina Ramsenthaler and Prof Irene Higginson, Department of…
